HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its HeartBeam System as a tool for assessing potential heart attacks at home. The designation, granted within 30 days of the company’s request, comes ahead of the FDA’s 60-day statutory review period and recognizes the potential of HeartBeam’s 3D ECG technology to enable physicians to evaluate signs of a possible heart attack when symptoms begin, regardless of the patient’s location.
The FDA’s Breakthrough Device Designation provides prioritized review and increased interaction with the agency as HeartBeam advances its heart attack assessment program. Importantly, the designation is a prerequisite for certain expedited Medicare coverage pathways, which could accelerate patient access to the technology if approved. HeartBeam expects to seek FDA alignment on the design of a multicenter pivotal study in the coming months and anticipates beginning patient enrollment shortly thereafter. If successful, the study is intended to support a future submission to expand the HeartBeam System indications to include heart attack assessment.
HeartBeam’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This allows physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The HeartBeam System already received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. Details on the intended use of the technology are available at https://www.heartbeam.com/indications.
The new designation matters because heart attacks often occur outside hospitals, and rapid assessment is critical for survival. By enabling at-home evaluation, HeartBeam’s technology could reduce delays in diagnosis and treatment, potentially saving lives and lowering healthcare costs. The FDA’s swift granting of the designation underscores the unmet need in cardiac care and the promise of HeartBeam’s approach.
HeartBeam holds over 20 issued patents related to technology enablement. The company’s progress is closely followed by investors, with the latest news and updates available in its newsroom at https://nnw.fm/BEAT. For the full press release, visit https://nnw.fm/FxKxf.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio within IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
